Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis

• Status: Completed
• Trial end date: 2018-06-23
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to describe the pharmacokinetics of the prescribed echinocandins for septic shock with secondary peritonitis for which intra-abdominal fungal infection is suspected or proven.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Nīmes
• Treatments: Caspofungin; Echinocandins; Micafungin

Criteria

Inclusion Criteria:

• The emergency inclusion procedure was correctly applied according to French law (signature of consent form by a patient-designated trusted person or a family member, or a medical decision to proceed with patient inclusion if the latter two persons are unavailable) ---- OR ---- signature of the consent form by the patient

• The patient must be insured or beneficiary of a health insurance plan

• The patient is 18 years of age or older

• The patient has beed admitted to the ICU for septic shock accompanying secondary peritonitis

• Patient requiring antifungal treatment via echinocandins (caspofungin or micafungin)

• A venous or arterial access for blood sampling is already in place for routine care

Exclusion Criteria:

• The patient is participating in an interventional study that may affect the results of the present study, or has participated in such a study within the past 3 months

• The patient is under judicial protection, or is an adult under guardianship

• The patient is pregnant, parturient or breastfeeding

• Moribund patient

• Known positive serology for human immunodeficiency virus (HIV)

• Known positive serology for hepatitis C

• Known diagnosis for tuberculosis